New hope for patients with Tough-to-Treat blood cancer
NCT ID NCT07420959
Summary
This study is testing a new drug called ABBV-383 for people with Waldenström macroglobulinemia, a rare blood cancer, that has come back or stopped responding to other treatments. The first part of the trial will find the safest dose, and the second part will see how well the drug works to control the cancer. It is for adults whose cancer has progressed despite prior therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.